Additionally, irrespective of the LS or ES group, STAT3 gene mutation carriers exhibited significantly shorter OS than non-carriers (Fig. 5E and F), and LS patients with AURKA or PMS2 mutations had poorer chemotherapy outcomes compared to non-carriers (Fig. S2A and S2C). The gene discussed is PMS2; the disease is Leigh syndrome.